---
schema_version: "secwatch.filing_event.v1"
accession: "0001724521-25-000039"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:49:47.971690+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcus Q4 2024 net loss $94M; casdatifan shows best-in-class potential in ccRCC

## Summary
- Revenue $36M for Q4 2024 ($31M Q4 2023); net loss widened to $94M from $81M.
- Cash & marketable securities $992M as of Dec 31, 2024, up from $866M year-end 2023.
- Casdatifan monotherapy in IO/VEGFR-TKI experienced ccRCC achieved 30%+ ORR, 9.7-month median PFS (50mg BID).
- Phase 3 PEAK-1 (casdatifan + cabozantinib vs cabo in post-IO ccRCC) expected to initiate Q2 2025.
- Domvanalimab/zimberelimab Phase 3 STAR-221 top-line data for 1L upper GI cancers expected 2026.

## SEC filing metadata
- accession: 0001724521-25-000039
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000039/0001724521-25-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000039/rcus-20250225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001724521-25-000039
- JSON: https://secwatch.observer/filing/0001724521-25-000039.json
- Plain text: https://secwatch.observer/filing/0001724521-25-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.